Form 8-K - Current report:
SEC Accession No. 0001104659-24-123742
Filing Date
2024-11-27
Accepted
2024-11-27 17:00:44
Documents
13
Period of Report
2024-11-21
Items
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2429671d1_8k.htm   iXBRL 8-K 31233
  Complete submission text file 0001104659-24-123742.txt   206913

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20241121.xsd EX-101.SCH 3027
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20241121_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20241121_pre.xml EX-101.PRE 22367
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2429671d1_8k_htm.xml XML 3685
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
Entero Therapeutics, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 241512204
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)